Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$57,057 Mln
P/E Ratio
33.45
P/B Ratio
2.26
Industry P/E
79.79
Debt to Equity
0.69
ROE
0.07 %
ROCE
3.89 %
Div. Yield
2 %
Book Value
87.78
EPS
5.95
CFO
$28,585.00 Mln
EBITDA
$32,854.00 Mln
Net Profit
$11,716.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
| -12.41 | -12.07 | -15.91 | -13.98 | -9.90 | -4.88 | 3.64 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Midcap 400
| -11.96 | -6.24 | -14.95 | -3.87 | 1.45 | 12.76 | 5.99 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
| -6.90 | -4.12 | 3.72 | 1.88 | -6.75 | 22.20 | 6.58 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 71.53 | 41,899.05 | 30.57 | 50.15 | |
| 411.49 | 32,741.38 | 37.83 | 57.66 | |
| 212.91 | 31,269.46 | 25.14 | 24.69 | |
| 215.95 | 35,134.20 | 49.99 | 13.63 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical... industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. Read more
President, CEO & Chairman
Mr. Thomas E. Polen Jr.
President, CEO & Chairman
Mr. Thomas E. Polen Jr.
Headquarters
Franklin Lakes, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Becton Dickinson and Company (BDX) stood at $ 62,329 Mln as on 31-Dec-24
The share price of Becton Dickinson and Company (BDX) is $198.71 (NYSE) as of 17-Apr-2025 16:10 EDT. Becton Dickinson and Company (BDX) has given a return of -9.9% in the last 3 years.
Becton Dickinson and Company (BDX) has a market capitalisation of $ 57,057 Mln as on 17-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Becton Dickinson and Company (BDX) is 2.26 times as on 17-Apr-2025, a 31% discount to its peers’ median range of 3.27 times.
The P/E ratio of Becton Dickinson and Company (BDX) is 33.45 times as on 17-Apr-2025, a 58% discount to its peers’ median range of 79.79 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Becton Dickinson and Company (BDX) and enter the required number of quantities and click on buy to purchase the shares of Becton Dickinson and Company (BDX).
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
The CEO & director of Mr. Thomas E. Polen Jr.. is Becton Dickinson and Company (BDX), and CFO & Sr. VP is Mr. Thomas E. Polen Jr..
There is no promoter pledging in Becton Dickinson and Company (BDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
4,171
|
|
|
3,590
|
|
|
3,274
|
|
|
3,106
|
| Becton Dickinson and Company (BDX) | Ratios |
|---|---|
|
Return on equity(%)
|
6.76
|
|
Operating margin(%)
|
12.14
|
|
Net Margin(%)
|
8.37
|
|
Dividend yield(%)
|
2
|
No, TTM profit after tax of Becton Dickinson and Company (BDX) was $0 Mln.
$-1.69
(
